22nd Century Group (XXII) is poised to benefit from a growing cannabis market and increased demand by cultivators for higher-yielding crops. The upcoming harvest, additional plant lines in 2022–23 and strategic partnerships should boost revenues and accelerate the commercialization of the company’s improved hemp/cannabis lines. Moreover, XXII’s recently announced entry into the less-regulated hops market significantly expands its total addressable market as it leverages its intellectual property (IP) and scale to increase product speed to market.
Written by
22nd Century Group |
Hemp and hops: Two of our favorite things
|
Biotechnology |
QuickView
13 October 2021 |
Share price graph
Share details
Business description
Bull
Bear
Analysts
|
||||||||||||||||||||||||||
22nd Century Group (XXII) is poised to benefit from a growing cannabis market and increased demand by cultivators for higher-yielding crops. The upcoming harvest, additional plant lines in 2022–23 and strategic partnerships should boost revenues and accelerate the commercialization of the company’s improved hemp/cannabis lines. Moreover, XXII’s recently announced entry into the less-regulated hops market significantly expands its total addressable market as it leverages its intellectual property (IP) and scale to increase product speed to market.
Accelerating hemp/cannabis commercialization
As North American cannabis markets continue their rapid growth, demand is increasing for plant genetics designed for industrial production. Earlier this year, XXII secured upstream partnerships to grow the first lines of high cannabidiol at its Colorado farm for the late 2021 harvest and additional lines in 2022–23, accelerating the commercialization of its improved hemp/cannabis plant lines as it now controls the complete upstream cannabis capability. Furthermore, XXII leveraged its IP assets by developing key strategic commercial partnerships with breeding partners, biotech firms, etc. Revenues of ~$4–6m in Q421 should be generated from its upfront IP licensing and the initial crop, ~15% of FY21 consensus revenue. Overall, XXII appears positioned to meet the growing demands for higher-yielding and disruptive plant lines.
A new franchise expands addressable market
In late August, XXII announced its expansion into the European hops market, its newest franchise area. Entry into the global hops market significantly expands the company’s total addressable market, as hops are a critical input for the $500m global brewing industry. Moreover, the hops market has much lower regulatory barriers than XXII’s other businesses and gives it an opportunity to leverage its IP, proprietary hop plant technology and scale to accelerate the speed to market and ‘bring hop breeding into the 21st century.’
Larger market provides upside potential
In August, XXII moved its listing from NYSE American to Nasdaq, aligning it with other growth-oriented science and technology companies. At the closing price of $2.94 on 12 October , the shares are up 42% year to date and trading at a P/revenue of ~9x in FY22e, in line with the company’s cannabis biotechnology peers. With the commercialization of potentially higher-yielding cannabis strains and expansion into a larger and less-regulated hops market, XXII could command higher valuations.
|
Consensus estimates
Source: 22nd Century Group, Refinitiv |
EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
||||||||||||
|
||||||||||||
Research: Healthcare
Kazia expects to release multiple data points from its paxalisib programme in Q4 CY21. These include final data from the 30-patient Phase II trial in newly diagnosed glioblastoma multiforme (GBM) patients, as well as initial data for paxalisib in the treatment of brain metastases (BMs). Additionally, the Phase I for EVT801 is expected to begin enrolment by year-end.